CONGRESS GUIDE

ERS International Congress 2016
DETAILED PROGRAMME
SUNDAY 04 SEPTEMBER, 2016
PA601
PA602
PA603
PA604
PA605
PA606
PA607
PA608
PA609
PA610
PA611
PA612
YKL-40 and CCL18 predict mortality in patients hospitalised with community-acquired pneumonia; an
observational analysis
Simone Spoorenberg (Nieuwegein, Netherlands), Simone Spoorenberg, Stefan Vestjens, Ger Rijkers, Bob Meek, Coline van
Moorsel, Jan Grutters, Willem Jan Bos
Critical review of the current management of pleural infection in a UK district general hospital. Applying the MIST
II (multicentre intrapleural sepsis trial) evidence to our current practice
Benjamin Peirce (Cambridge, United Kingdom), Benjamin Peirce, Thomas Pulimood, Clare Harris
Serum procalcitonin as a potential biomarker of surgery in parapneumonic pleural effusions
Arturo Cortes-Telles (Merida, Yucatan, Mexico), Arturo Cortes-Telles, Angel Emmanuel Vega-Sanchez, Jose Luis Che-
Morales, Danielle Aimee Manjarrez-Martin, Gary Kosai Vargas-Mendoza
Bacteremic vs. non-bacteremic pneumococcal pneumonia in immunocompetent patients: Predictive and prognostic
factors
Rosanel Amaro Rodriguez (Premia de Dalt (Barcelona), Spain), Rosanel Amaro Rodriguez, Adamatia Liapikou, Catia
Cilloniz, Albert Gabarrús, Framcesc Marco, Jacobo Sellarés, Eva Polverino, Javier Garau, Miquel Ferrer, Daniel M. Musher,
Antoni Torres
The risk factors of clinical practice for bacteremia in community- acquired pneumococcal pneumonia
Yasuyoshi Washio (Kurashiki, Japan), Yasuyoshi Washio, Akihiro Ito, Shogo Kumagai, Tadashi Ishida
Predisposing factors for bacteremia in patients with community-acquired pneumonia and positive pneumococcal
urinary antigen
Leyre Serrano Fernandez (Bilbao (Bizkaia), Spain), Leyre Serrano Fernandez, Rafael Zalacain, Alberto Capelastegi, Ainhoa
Gomez, Lorea Martinez-Indart, Marta Garcia, Ane Uranga, Pedro Pablo España, Luis Alberto Ruiz
Clinical impact of a prediction score for drug-resistance in community-onset pneumonia
Brandon Webb (Murray, United States of America), Brandon Webb, Jeff Sorensen, Herman Post, Peter Jones, Dominika
Swistun, Al Jephson, Nathan Dean
Community-acquired pneumonia due to multidrug and non-multidrug resistant pseudomonas aeruginosa
Catia Cilloniz Campos (Barcelona, Spain), Catia Cilloniz Campos, Albert Gabarrus, Adamanthia Liapikou, Daniel Martinez,
Michael Niederman, Antoni Torres
Effect of giving antibiotics within 4 hours to patients with community-acquired pneumonia on mortality, length of
stay and critical care admission
Olivia George (Manchester, United Kingdom), Olivia George, Ian Webster
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Cornelis H. van Werkhoven (Utrecht, Netherlands), Cornelis H. van Werkhoven, Ewoudt M.W. van de Garde, Jan Jelrik
Oosterheert, Douwe F. Postma, Marc J.M. Bonten
Empiric penicillin monotherapy of CAP is not associated with increased mortality; experiences from the
retrospective CAP-North cohort
Gertrud Baunbæk-Knudsen (FREDERIKSBERG, Denmark), Gertrud Baunbæk-Knudsen, Andreas Vestergaard Jensen,
Stine Andersen, Pelle Trier Petersen, Bjarne Ørskov Lindhardt, Christian von Plessen, Gernot Rohde, Pernille Ravn
No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure
Meng-Jer Hsieh (Taipei, Taiwan), Meng-Jer Hsieh, Chun-Chen Yu, Han-Chung Hu, Ying-Huang Thai
PA613
Evolutionary trend of invasive pneumococcal disease according to serotypes
Maria Jose Galvez Medina (Madrid, Spain), Maria Jose Galvez Medina, Angela Ramos Pinedo, Jose Francisco Valverde
Canovas, Elia Perez, Javier Solano, Mercedes Izquierdo, Nurua Echave, Marta Inmaculada Hernandez
T-01 Session 165 12:50 - 14:40
Thematic Poster: Clinical characteristics of asthma
Chairs : Chung-Wai Chow (Toronto, ON, Canada), Mohamed Al-Moamary (Riyadh, Saudi Arabia), Kristián Brat (Brno, Czech
Republic), Laura Ciobanu (Iasi, Romania)
PA617
A case diagnoed ACOS with omelizumab treatment
bilge sal k (izmir, Turkey), Bilge Salik, Berna Komurcuoglu, Enver Yalniz
PA618
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or
partly controlled asthma
Katerina Athanassiou (Pikermi, Greece), Katerina Athanassiou, Luigi Silvestro, Simona Rizea Savu
49 26.08.2016